Generic drug: Antihemophilic Factor
Brand name: Afstyla
What is Afstyla (Antihemophilic Factor), and how does it work?
- Afstyla, Antihemophilic Factor (Recombinant), Single Chain is a medicine used to replace clotting Factor VIII that is missing in patients with hemophilia A.
- Hemophilia A is an inherited bleeding disorder that prevents blood from clotting normally.
- Does not contain human plasma-derived proteins or albumin.
- Your healthcare provider may give you this medicine when you have surgery.
- Is used to treat and control bleeding in all patients with hemophilia A.
- Can reduce the number of bleeding episodes when used regularly (prophylaxis) and reduce the risk of joint damage due to bleeding.
- Is not used to treat von Willebrand disease.
What are the side effects of Afstyla?
- Allergic reactions may occur. Immediately stop treatment and call your healthcare provider right away if you get a rash or hives, itching, tightness of the chest or throat, difficulty breathing, light-headedness, dizziness, nausea, or decrease in blood pressure.
- Your body may form inhibitors to Factor VIII. An inhibitor is a part of the body's defense system. If you form inhibitors, it may stop this medicine from working properly. The greatest risk of this occurring is in previously untreated patients. Your healthcare provider may need to test your blood for inhibitors from time to time.
- Common side effects are dizziness and allergic reactions.
- These are not the only side effects possible. Tell your healthcare provider about any side effect that bothers you or does not go away.
What is the dosage for Afstyla?
For intravenous use after reconstitution only.
- Dose and duration of treatment depend on the severity of the Factor VIII deficiency, the location and extent of bleeding, and the patient's clinical condition.
- Each vial of Afstyla states the actual amount of Factor VIII activity in International Units (IU) as determined by chromogenic assay. One IU corresponds to the activity of Factor VIII contained in 1 milliliter (mL) of normal human plasma.
- Plasma Factor VIII levels can be monitored using either a chromogenic assay or a one-stage clotting assay – routinely used in US clinical laboratories. If the one-stage clotting assay is used, multiply the result by a conversion factor of 2 to determine the patient's Factor VIII activity level.
Calculating Required Dose
The expected in vivo peak increase in Factor VIII level expressed as IU/dL (or % of normal) is estimated using the following formula:
Estimated Increment of Factor VIII (IU/dL or % of normal) = [Total Dose (IU)/body weight (kg)] × 2 (IU/dL per IU/kg)
The dose to achieve a desired in vivo peak increase in Factor VIII level may be calculated using the following formula:
Dose (IU) = body weight (kg) × Desired Factor VIII rise (IU/dL or % of normal) × 0.5 (IU/kg per IU/dL)
- The calculation of the required dose of Factor VIII is based on the empirical finding that 1 IU Factor VIII per kg body weight raises the plasma Factor VIII level by 2 IU/dL.
- The amount of Afstyla to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.
On-Demand Treatment And Control Of Bleeding Episodes
A guide for dosing Afstyla in the treatment and control of bleeding episodes is provided in Table 1. Consideration should be given to maintaining a Factor VIII activity at or above the target range.
Table 1. Dosing for On-demand Treatment and Control of Bleeding Episodes
|Type of Bleeding Episode||Factor VIII Activity
(% or IU/dL)
|Frequency of Doses (hours)|
|Uncomplicated hemarthrosis, minor muscle bleeding or oral bleeding||20-40||Repeat injection every 12-24 hours until the bleeding is resolved.|
|Muscle bleeding (except iliopsoas), hemarthrosis, or mild trauma||30-60||Repeat injection every 12-24 hours until the bleeding is resolved.|
|Limb threatening hemorrhage, deep muscle bleeding (including iliopsoas), intracranial and retropharyngeal bleeding, fractures or head trauma||60-100||Repeat injection every 8-24 hours until bleed is resolved.|
- Adults and adolescents (≥12 years): The recommended starting regimen is 20 to 50 IU per kg of Afstyla administered 2 to 3 times weekly.
- Children (<12 years): The recommended starting regimen is 30 to 50 IU per kg of Afstyla administered 2 to 3 times weekly. More frequent or higher doses may be required in children <12 years of age to account for the higher clearance in this age group.
- The regimen may be adjusted based on patient response.
Perioperative Management Of Bleeding
A guide for dosing Afstyla during surgery (perioperative management of bleeding) is provided in Table 2. Consideration should be given to maintaining a Factor VIII activity at or above the target range.
Table 2. Target Factor VIII Activity Levels for Perioperative Management of Bleeding
|Type of Surgery||Factor VIII Activity
(% or IU/dL)
|Frequency of Doses (hours) / Duration of Therapy (days)|
|(including tooth extraction)||30-60||Repeat injection every 24 hours for at least 1 day, until healing is achieved.|
|(intracranial, intra-abdominal, intrathoracic, or joint-replacement)||80-100||Repeat injection every 8-24 hours until adequate wound healing, then continue therapy for at least another 7 days to maintain a Factor VIII activity of 30-60% (IU/dL).|
Is Afstyla safe to use while pregnant or breastfeeding?
- There are no data with Afstyla use in pregnant women to inform on drug-associated risk.
- There is no information regarding the excretion of Afstyla in human milk, the effect on the breastfed infant, or the effects on milk production.
- The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Afstyla and any potential adverse effects on the breastfed infant from Afstyla or from the underlying maternal condition.
Afstyla, Antihemophilic Factor (Recombinant), Single Chain is a medicine used to replace clotting Factor VIII that is missing in patients with hemophilia A, a blood disorder that causes difficulty in the blood clotting. Side effects of Afstla include allergic reactions and dizziness.
Multimedia: Slideshows, Images & Quizzes
Hemophilia Quiz: Test Your IQ of This Blood Disorder
What happens within the body in a person who has hemophilia? Take this quiz to learn about this rare blood disorder.
Blood and Bleeding Disorders Quiz
Exactly what is sickle cell anemia? Learn about sickle cell and other diseases by testing your IQ with the Blood and Bleeding...
Picture of Blood Clot
Blood that has been converted from a liquid to a solid state. See a picture of Blood Clot and learn more about the health topic.
Blood Clots: 4 Signs You Could Have One
Blood clots can be deadly medical emergencies that can form in different parts of your body. Learn the warning signs that you...
Blood Disorders: Types, Symptoms, and Treatments
Some blood disorders are forms of cancer. Others are benign. Find out what happens and why.
Related Disease Conditions
Varices are dilated blood vessels usually in the esophagus or stomach. Symptoms of bleeding varices include vomiting blood, black stools, low blood pressure, shock, and rapid heart rate. Bleeding varices are a medical emergency. Treatment may involve liver transplant, devascularization, distal splenorenal shunt, banding, sclerotherapy, or transjugular intrahepatic protosystemic shunt.
Blood Clots (in the Leg)
Blood clots can occur in the venous and arterial vascular system. Blood clots can form in the heart, legs, arteries, veins, bladder, urinary tract and uterus. Risk factors for causes of blood clots include high blood pressure and cholesterol, diabetes, smoking, and family history. Symptoms of a blood clot depend on the location of the clot. Some blood clots are a medical emergency. Blood clots are treated depending upon the cause of the clot. Blood clots can be prevented by lowering the risk factors for developing blood clots.
Internal bleeding occurs when an artery or vein is damaged and blood to escapes the circulatory system and collects inside the body. Internal bleeding can be caused by a variety of situations such as blunt trauma, deceleration trauma, medications, fractures, and spontaneous bleeding. Treatment of internal bleeding depends on the cause of the bleeding.
Hemophilia A and B (Bleeding Disorders)
Hemophilia is defined as one of a group of inherited bleeding disorders. Hemophilia A and hemophilia B are inherited in an X-linked recessive genetic pattern. Symptoms of hemophilia include bleeding into the: joints, muscles, GI or urinary tract, or brain or skull. Hemophilia treatment generally involves the replacement of blood clotting factors.
Bilirubin is a waste product of the normal breakdown of red blood cells in the liver. Normal bilirubin levels vary from lab to lab, and range from around 0.2 to 1.2 mg/dL. High levels of bilirubin can be diagnosed with a bilirubin blood test. Causes of elevated levels of bilirubin in the blood can be caused by infections, viral hepatitis, anemia, genetic diseases, and liver problems. Symptoms of elevated bilirubin levels depend on the cause; however, jaundice is a common sign. Treatment for elevated bilirubin levels depend on the cause.
What Does a Blood Clot Feel Like?
Blood clots are semi-solid masses of blood that may be immobile (thrombosis) and impede blood flow or dislodge to other parts of the body (embolism). Deep vein clots, if dislodged, can travel through veins through the lungs to the arteries in the lungs. This is referred to as a pulmonary embolism and can be deadly. Blood clots can also lead to a heart attack or stroke.
What Are the 3 Types of Hemophilia?
Hemophilia is a rare bleeding disorder in which the blood doesn't clot normally. It mainly affects males and is rare in females. Hemophilia is sometimes called “the royal disease.” Several royal families of England, Germany, Russia, and Spain in the 19th and 20th centuries had members afflicted with hemophilia.
Treatment & Diagnosis
Medications & Supplements
Latest Medications News
Daily Health News
Health Solutions From Our Sponsors
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.